Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
4.760
+0.310 (6.97%)
At close: Aug 13, 2025, 4:00 PM
4.540
-0.220 (-4.62%)
After-hours: Aug 13, 2025, 5:19 PM EDT
Lantern Pharma Employees
Lantern Pharma had 24 employees as of December 31, 2024. The number of employees increased by 3 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
3
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$828,216
Market Cap
51.34M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LTRN News
- 2 hours ago - Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - Business Wire
- 7 days ago - Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial - Business Wire
- 9 days ago - Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™ - Business Wire
- 13 days ago - Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300 - Business Wire
- 16 days ago - Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors - Business Wire
- 21 days ago - Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire
- 23 days ago - Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - Business Wire
- 4 weeks ago - Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - Business Wire